SGLT2 inhibitors are a modern class of drugs which were originally introduced as a treatment for type 2 diabetes mellitus, as they block glucose reabsorption in the proximal convoluted tubule of the kidney, increasing glycosuria and reducing blood glucose levels [104]. This evidence concerns the gene SLC5A2 and diabetes mellitus.